{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T02:56:12Z","timestamp":1773975372272,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00210-024-03021-x","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T10:02:24Z","timestamp":1709114544000},"page":"6107-6119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Exploring the therapeutic potential of SGLT2 inhibitors in cancer treatment: integrating in silico and in vitro investigations"],"prefix":"10.1007","volume":"397","author":[{"given":"Prasanna","family":"Mohite","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2858-678X","authenticated-orcid":false,"given":"Deepak K.","family":"Lokwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2614-1920","authenticated-orcid":false,"given":"Nikhil S.","family":"Sakle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"issue":"7","key":"3021_CR1","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.3390\/biomedicines11071867","volume":"11","author":"D Basak","year":"2023","unstructured":"Basak D, Gamez D, Deb S (2023) SGLT2 Inhibitors as potential anticancer agents. Biomedicines 11(7):1867. https:\/\/doi.org\/10.3390\/biomedicines11071867","journal-title":"Biomedicines"},{"issue":"23","key":"3021_CR2","doi-asserted-by":"publisher","first-page":"5811","DOI":"10.3390\/cancers14235811","volume":"14","author":"M Dutka","year":"2022","unstructured":"Dutka M, Bobi\u0144ski R, Francuz T, Garczorz W, Zimmer K, Ilczak T, \u0106wiertnia M, Hajduga MB (2022) SGLT-2 inhibitors in cancer treatment-mechanisms of action and emerging new perspectives. Cancers (basel) 14(23):5811. https:\/\/doi.org\/10.3390\/cancers14235811","journal-title":"Cancers (basel)"},{"key":"3021_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fonc.2015.00023","volume":"5","author":"T Furukawa","year":"2015","unstructured":"Furukawa T (2015) Impacts of activation of the mitogen-activated protein kinase pathway in pancreatic cancer. Front Oncol 5:23. https:\/\/doi.org\/10.3389\/fonc.2015.00023","journal-title":"Front Oncol"},{"issue":"2 Pt 1","key":"3021_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.gene.2015.08.063","volume":"575","author":"M Haase","year":"2016","unstructured":"Haase M, Fitze G (2016) HSP90AB1: Helping the good and the bad. Gene 575(2 Pt 1):171\u2013186. https:\/\/doi.org\/10.1016\/j.gene.2015.08.063","journal-title":"Gene"},{"issue":"1","key":"3021_CR5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/mt.2010.216","volume":"19","author":"G Kallifatidis","year":"2011","unstructured":"Kallifatidis G, Labsch S, Rausch V, Mattern J, Gladkich J, Moldenhauer G et al (2011) Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol Ther 19(1):188\u2013195. https:\/\/doi.org\/10.1038\/mt.2010.216","journal-title":"Mol Ther"},{"issue":"Pt1","key":"3021_CR6","doi-asserted-by":"publisher","first-page":"114889","DOI":"10.1016\/j.ejmech.2022.114889","volume":"245","author":"RA Kardile","year":"2023","unstructured":"Kardile RA, Sarkate AP, Lokwani DK, Tiwari SV, Azad R, Thopate SR (2023) Design, synthesis, and biological evaluation of novel quinoline derivatives as small molecule mutant EGFR inhibitors targeting resistance in NSCLC: in vitro screening and ADME predictions. Eur J Med Chem 245(Pt1):114889. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114889","journal-title":"Eur J Med Chem"},{"issue":"8","key":"3021_CR7","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1021\/ci300604z","volume":"53","author":"DR Koes","year":"2013","unstructured":"Koes DR, Baumgartner MP, Camacho CJ (2013) Lessons learned in empirical scoring with Smina from the CSAR 2011 benchmarking exercise. J Chem Inf Model 53(8):1893\u20131904. https:\/\/doi.org\/10.1021\/ci300604z","journal-title":"J Chem Inf Model"},{"issue":"4 Suppl 2","key":"3021_CR8","first-page":"S37","volume":"1","author":"S Kopetz","year":"2007","unstructured":"Kopetz S (2007) Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic. J Gastrointest Cancer 1(4 Suppl 2):S37-41","journal-title":"J Gastrointest Cancer"},{"issue":"1","key":"3021_CR9","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1038\/s41598-022-06811-6","volume":"12","author":"J Leem","year":"2022","unstructured":"Leem J, Jung W, Park HJ, Kim K (2022) A network pharmacology-based approach to explore mechanism of action of medicinal herbs for alopecia treatment. Sci Rep 12(1):2852. https:\/\/doi.org\/10.1038\/s41598-022-06811-6","journal-title":"Sci Rep"},{"issue":"1","key":"3021_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/ecsoc-27-16049","volume":"14","author":"DK Lokwani","year":"2023","unstructured":"Lokwani DK, Chavan SR, Sarkate AP, Natarajan PM, Umapathy VR, Jain SP (2023) Virtual screening of natural compounds as potential SARS-CoV-2 main protease inhibitors: a molecular docking and molecular dynamics simulation guided approach. Chem Proc 14(1):85. https:\/\/doi.org\/10.3390\/ecsoc-27-16049","journal-title":"Chem Proc"},{"issue":"1 Suppl 2","key":"3021_CR11","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1590\/0001-3765201820170823","volume":"90","author":"LG Magalhaes","year":"2018","unstructured":"Magalhaes LG, Ferreira LLG, Andricopulo AD (2018) Recent advances and perspectives in cancer drug design. An Acad Bras Cienc 90(1 Suppl 2):1233\u20131250. https:\/\/doi.org\/10.1590\/0001-3765201820170823","journal-title":"An Acad Bras Cienc"},{"key":"3021_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.virol.2020.12.006","volume":"555","author":"SA More","year":"2021","unstructured":"More SA, Patil AS, Sakle NS, Mokale SN (2021) Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs. Virology 555:10\u201318. https:\/\/doi.org\/10.1016\/j.virol.2020.12.006","journal-title":"Virology"},{"key":"3021_CR13","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.phrs.2016.06.018","volume":"111","author":"P Poornima","year":"2016","unstructured":"Poornima P, Kumar JD, Zhao Q, Blunder M, Efferth T (2016) Network pharmacology of cancer: from understanding of complex interactomes to design of multi-target specific therapeutics from nature. Pharmacol Res 111:290\u2013302. https:\/\/doi.org\/10.1016\/j.phrs.2016.06.018","journal-title":"Pharmacol Res"},{"issue":"1","key":"3021_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00894-021-05010-w","volume":"28","author":"HO Rasul","year":"2021","unstructured":"Rasul HO, Aziz BK, Ghafour DD, Kivrak A (2021) In silico molecular docking and dynamic simulation of eugenol compounds against breast cancer. J Mol Model 28(1):17. https:\/\/doi.org\/10.1007\/s00894-021-05010-w","journal-title":"J Mol Model"},{"issue":"3","key":"3021_CR15","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s11030-022-10475-9","volume":"27","author":"HO Rasul","year":"2023","unstructured":"Rasul HO, Aziz BK, Ghafour DD, Kivrak A (2023) Discovery of potential mTOR inhibitors from Cichorium intybus to find new candidate drugs targeting the pathological protein related to the breast cancer: an integrated computational approach. Mol Divers 27(3):1141\u20131162. https:\/\/doi.org\/10.1007\/s11030-022-10475-9","journal-title":"Mol Divers"},{"key":"3021_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.canlet.2021.07.035","volume":"519","author":"D Ren","year":"2021","unstructured":"Ren D, Sun Y, Zhang D, Li D, Liu Z, Jin X, Wu H (2021) SGLT2 promotes pancreatic cancer progression by activating the Hippo signaling pathway via the hnRNPK-YAP1 axis. Cancer Lett 519:277\u2013288. https:\/\/doi.org\/10.1016\/j.canlet.2021.07.035","journal-title":"Cancer Lett"},{"key":"3021_CR17","doi-asserted-by":"publisher","first-page":"17217","DOI":"10.1038\/s41598-020-74251-1","volume":"10","author":"NS Sakle","year":"2020","unstructured":"Sakle NS, More SA, Mokale SN (2020) A network pharmacology-based approach to explore potential targets of Caesalpinia pulcherima: an updated prototype in drug discovery. Sci Rep 10:17217. https:\/\/doi.org\/10.1038\/s41598-020-74251-1","journal-title":"Sci Rep"},{"issue":"30","key":"3021_CR18","doi-asserted-by":"publisher","first-page":"E4111","DOI":"10.1073\/pnas.1511698112","volume":"112","author":"C Scafoglio","year":"2015","unstructured":"Scafoglio C, Hirayama BA, Kepe V, Liu J, Ghezzi C, Satyamurthy N et al (2015) Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci USA 112(30):E4111\u2013E4119. https:\/\/doi.org\/10.1073\/pnas.1511698112","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"3021_CR19","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.3390\/ijms21124507","volume":"21","author":"BY Shorning","year":"2020","unstructured":"Shorning BY, Dass MS, Smalley MJ, Pearson HB (2020) The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci 21(12):4507. https:\/\/doi.org\/10.3390\/ijms21124507","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3021_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21708","journal-title":"CA Cancer J Clin"},{"key":"3021_CR21","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/1756-0500-5-367","volume":"5","author":"AW Sousa da Silva","year":"2012","unstructured":"Sousa da Silva AW, Vranken WF (2012) ACPYPE - AnteChamber PYthon Parser InterfacE. BMC Res Notes 5:367. https:\/\/doi.org\/10.1186\/1756-0500-5-367","journal-title":"BMC Res Notes"},{"issue":"17","key":"3021_CR22","doi-asserted-by":"publisher","first-page":"10132","DOI":"10.3390\/ijms231710132","volume":"23","author":"S Stanciu","year":"2022","unstructured":"Stanciu S, Ionita-Radu F, Stefani C, Miricescu D, Stanescu-Spinu II, Greabu M, Ripszky Totan A, Jinga M (2022) Targeting PI3K\/AKT\/mTOR signaling pathway in pancreatic cancer: from molecular to clinical aspects. Int J Mol Sci 23(17):10132. https:\/\/doi.org\/10.3390\/ijms231710132","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3021_CR23","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/17460441.2020.1704729","volume":"15","author":"A Talevi","year":"2020","unstructured":"Talevi A, Bellera CL (2020) Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics. Expert Opin Drug Discov 15(4):397\u2013401. https:\/\/doi.org\/10.1080\/17460441.2020.1704729","journal-title":"Expert Opin Drug Discov"},{"issue":"10","key":"3021_CR24","doi-asserted-by":"publisher","first-page":"8653","DOI":"10.1080\/10406638.2022.2150238","volume":"43","author":"NM Thorat","year":"2023","unstructured":"Thorat NM, Khodade VS, Ingale AP, Lokwani DK, Sarkate AP, Thopate SR (2023) Molecular docking studies and application of 6-(1-Arylmethanamino)-2-phenyl-4 H -chromen-4-ones as potent antibacterial Agents. Polycycl Aromat Compd 43(10):8653\u20138666. https:\/\/doi.org\/10.1080\/10406638.2022.2150238","journal-title":"Polycycl Aromat Compd"},{"key":"3021_CR25","doi-asserted-by":"publisher","first-page":"128747","DOI":"10.1016\/j.bmcl.2022.128747","volume":"67","author":"SV Tiwari","year":"2022","unstructured":"Tiwari SV, Sarkate AP, Lokwani DK, Pansare DN, Gattani SG, Sheaikh SS et al (2022) Explorations of novel pyridine-pyrimidine hybrid phosphonate derivatives as aurora kinase inhibitors. Bioorganic Med Chem Lett 67:128747. https:\/\/doi.org\/10.1016\/j.bmcl.2022.128747","journal-title":"Bioorganic Med Chem Lett"},{"issue":"10","key":"3021_CR26","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","volume":"17","author":"MS Vald\u00e9s-Tresanco","year":"2021","unstructured":"Vald\u00e9s-Tresanco MS, Vald\u00e9s-Tresanco ME, Valiente PA, Moreno E (2021) Gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS. J Chem Theory Compu 17(10):6281\u20136291. https:\/\/doi.org\/10.1021\/acs.jctc.1c00645","journal-title":"J Chem Theory Compu"},{"issue":"1","key":"3021_CR27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12935-022-02496-z","volume":"22","author":"Y Wang","year":"2022","unstructured":"Wang Y, Yang L, Mao L, Zhang L, Zhu Y, Xu Y et al (2022) SGLT2 inhibition restrains thyroid cancer growth via G1\/S phase transition arrest and apoptosis mediated by DNA damage response signaling pathways. Cancer Cell Int 22(1):74. https:\/\/doi.org\/10.1186\/s12935-022-02496-z","journal-title":"Cancer Cell Int"},{"issue":"9","key":"3021_CR28","doi-asserted-by":"publisher","first-page":"a031435","DOI":"10.1101\/cshperspect.a031435","volume":"8","author":"AM Waters","year":"2018","unstructured":"Waters AM, Der CJ (2018) KRAS: The critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb Perspect Med 8(9):a031435. https:\/\/doi.org\/10.1101\/cshperspect.a031435","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5","key":"3021_CR29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/cancers9050052","volume":"9","author":"P Wee","year":"2017","unstructured":"Wee P, Wang Z (2017) Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (basel) 9(5):52. https:\/\/doi.org\/10.3390\/cancers9050052","journal-title":"Cancers (basel)"},{"key":"3021_CR30","doi-asserted-by":"publisher","first-page":"110821","DOI":"10.1016\/j.biopha.2020.110821","volume":"132","author":"J Zhou","year":"2020","unstructured":"Zhou J, Zhu J, Yu SJ, Ma HL, Chen J, Ding XF et al (2020) Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK\/mTOR pathway. Biomed Pharmacother 132:110821. https:\/\/doi.org\/10.1016\/j.biopha.2020.110821","journal-title":"Biomed Pharmacother"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03021-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03021-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03021-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T16:10:45Z","timestamp":1723824645000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03021-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["3021"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03021-x","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]},"assertion":[{"value":"12 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}